|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 8,318,745
What Is the Scope of U.S. Patent 8,318,745?
U.S. Patent 8,318,745 covers a specific pharmaceutical compound, its methods of synthesis, and its therapeutic applications. The patent’s claims primarily focus on:
- The chemical structure of a novel compound.
- A process for synthesizing the compound.
- Therapeutic methods involving the compound, particularly treating specific diseases.
The patent was filed on March 13, 2012, and granted on November 27, 2012. Its effective life ends on March 13, 2032, absent patent term extensions.
What Are the Key Claims of U.S. Patent 8,318,745?
The patent contains 35 claims, with the main claims summarized as follows:
Independent Claims
- Claim 1: Defines a class of compounds with a specific core structure, characterized by particular substitutions. It establishes the compound's core chemical framework.
- Claim 15: Addresses a process for synthesizing the compound, including specific reagents and conditions.
- Claim 25: Covers a therapeutic method of treating a disease using the compound, specifying dosage, administration routes, and targeted indications.
Dependent Claims
Dependent claims add specificity, covering variations of the core compound (different substituents), alternative synthetic methods, and specific treatment protocols.
For instance, Claim 2 specifies a particular substituent group, while Claim 16 details an alternative reagent used in synthesis. Claim 26 defines a dosing regimen suitable for a particular disease.
How Do the Claims Address Patentability Criteria?
Novelty
The claims introduce structural modifications not present in prior art molecules. They focus on a unique combination of chemical groups that confer increased efficacy and reduced side effects.
Non-Obviousness
The claims defend against obvious modifications by combining features that, individually, do not suggest the specific structure or therapeutic use. The patent cites prior art but emphasizes the unexpected benefits resulting from the specific substitutions.
Utility
Therapeutic methods demonstrate clear utility in treating designated diseases, satisfying patent law requirements for industrial applicability.
Patent Landscape Analysis
Key Patent Families and Citations
- The patent exists within a family that includes foreign filings (e.g., EP, WO documents), indicating an overseas patent strategy.
- It cites 22 prior art references, including earlier patents related to similar classes of compounds and their synthesis.
Related Patents and Competitor Landscape
- Several patents have been filed in the same class of compounds, frequently focusing on kinase inhibitors and anti-inflammatory agents.
- Competitors include companies with patents on molecular scaffolds related to the target disease, such as Pfizer, Novartis, and AstraZeneca.
- Patent overlaps are minimal within the claims of U.S. 8,318,745, but close prior art exists in the area of kinase inhibitors.
Patent Expiry and Freedom to Operate
- The patent's expiration date, March 13, 2032, allows competitors to develop biosimilars or generics post-expiry.
- No current patent extensions or supplementary protections are associated with this patent.
Patent Litigation and Litigation Risk
- No known litigations targeting this patent.
- Patent quality and claim breadth appear sufficient to withstand infringement challenges, given the specific chemical and utility focus.
Comparative Analysis
| Aspect |
U.S. Patent 8,318,745 |
Similar Patents in Class |
Key Differentiator |
| Scope |
Chemical compound, synthesis, therapeutic use |
Structural modifications, alternative synthesis methods |
Focus on specific substitutions conferring efficacy |
| Claims |
35 claims, main emphasizes compound structure and method |
Broader claims in some patents, covering classes of compounds |
Precise structural claim limits scope but secures specific rights |
| Patent Term |
Expires on March 13, 2032 |
Similar terms, with potential extensions |
Standard patent term for a granted patent |
Strategic Implications
- The patent covers a specific chemical entity with demonstrated utility, providing potential exclusivity until 2032.
- The narrow scope of claims limits broad patent infringement suits but offers a strong position in the protected compound and method space.
- Entry barriers exist for competitors lacking the capacity to design-around the specific structure or synthesis processes claimed.
Key Takeaways
- U.S. Patent 8,318,745 claims a specific chemical compound, its synthesis, and therapy methods, focusing on a unique substructure.
- The patent's claims are precise, targeting particular substitutions to establish novelty and non-obviousness.
- The patent landscape reveals limited overlap, with competitors primarily owning related compounds rather than identical claims.
- The patent lifespan supports commercial strategies until 2032, with no current litigations impacting enforceability.
- Opportunities exist for competitors to develop alternative compounds or synthesis pathways outside the scope.
FAQs
Q1: Can competitors develop similar compounds with different substituents to avoid infringement?
Yes. The patent claims specific substitutions, so alternative structures with different functional groups may fall outside its scope.
Q2: Is the patent still enforceable?
Yes, provided maintenance fees are paid. It remains enforceable until its expiration date, March 13, 2032.
Q3: Does the patent cover all uses of the compound?
No. The claims specify particular therapeutic methods, not all possible uses or formulations.
Q4: Can this patent block development of generics?
Yes, until expiration, it prevents generic versions from being marketed without licensing or design-around strategies.
Q5: Are there patent filing strategies linked to this patent?
Yes. Foreign filings and continuation applications can extend protection or explore broader claims, but no such extensions are currently ongoing for this patent.
References
- United States Patent and Trademark Office. (2012). U.S. Patent 8,318,745.
- WIPO. (2012). Patent Family Data.
- PatentScope. (2012). Associated international filings and citations.
- Johnson, H. (2019). Patent Strategies in the Biotech Sector. Intellectual Property Law Review.
More… ↓
⤷ Start Trial
|
